Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process

@article{Mantovani2009ImmuneSA,
  title={Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process},
  author={Stefania Mantovani and Silvia Garbelli and Alessandra Pasini and Dario Alimonti and Cesare Perotti and Mario Melazzini and Caterina Bendotti and Gabriele Mora},
  journal={Journal of Neuroimmunology},
  year={2009},
  volume={210},
  pages={73-79}
}

Immune system alterations in amyotrophic lateral sclerosis

Evidence supporting the immune system as an important part of ALS disease mechanism is provided and a hypothesis to direct the way for further studies is presented.

Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients’ peripheral blood

The hypothesis, in a subpopulation of patients, DCs recruited at the diseased tissue produce high levels of CCL-2 and IL-8 and contribute to the inflammatory process promoting the recruitment of other inflammatory cells, and this molecule could be a target for treatment of CNS inflammation.

Peripheral monocytes are functionally altered and invade the CNS in ALS patients

The circulating monocytes are found to be deregulated in ALS regarding subtype constitution, function and gene expression and application of human immunoglobulins or fusion proteins containing only the human Fc, but not the Fab antibody fragment increased CNS invasion of peripheral monocytes and delayed the disease onset.

Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis

The immune profile in ALS was shifted towards a Th1/Th17 cell-mediated pro-inflammatory immune response and correlated to disease severity and progression and large prospective studies are needed to confirm these findings.

The Peripheral Immune System and Amyotrophic Lateral Sclerosis

There is strong preclinical evidence of benefit from immune modulation and further trials are currently underway, and their potential as future therapeutic targets for clinical intervention are reviewed.

The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential

Evidence has demonstrated that in ALS patients Tregs are dramatically and progressively reduced in number and are less effective in promoting immune suppression, and these cells are now considered a promising therapeutic target for neuroprotection in ALS.

Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis

An update on the role of this crosstalk between the CNS and peripheral immune responses in ALS is provided and changes in the composition of gut microbiota are discussed because these can directly or indirectly influence this crossstalk.

Immunological Aspects in Amyotrophic Lateral Sclerosis

The role of the immune system in ALS pathogenesis and the tight coupling of immunity and central nervous system barrier function is described.

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation

Abstract Several studies suggest a role for the peripheral immune system in the pathophysiology of amyotrophic lateral sclerosis. However, comprehensive studies investigating the intrathecal immune

The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis

Preliminary data suggest that the levels of active CD11b+ monocytes and NCM in the blood predict different clinical outcomes in ALS, including shorter survival in a multivariable and univariate analysis.
...

References

SHOWING 1-10 OF 47 REFERENCES

Inflammatory processes in amyotrophic lateral sclerosis

Anti‐inflammatory agents may have a role to play in treating ALS, and COX‐2 is a particularly attractive target because of its marked increase in ALS spinal cord.

Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS)

Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets

The findings seem to support the conclusion that the immune alterations in idiopathic ALS patients are related to the mechanisms of the disease and not to complications of its evolution.

Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue.

Evidence of immune-effector changes in ALS is provided, consistent with an autoimmune or slow virus theory of the disorder, but may reflect only secondary changes.

Neuroinflammation and Peripheral Immune Infiltration in Parkinson's Disease: An Autoimmune Hypothesis

It is proposed that peripheral immunity contributes to the degenerative process of PD and may be responsible for the progressive nature of the disease.

Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice

A profound and progressive immunodeficiency is operative in G93A-SOD1 mice and is linked to T cell dysfunction and the failure to elicit COP-1 neuroprotective immune responses, and abilities to improve neurological function and life expectancy by reconstitution with activated T cells do provide opportunities for therapeutic intervention.

T Cell Receptor BV Gene Rearrangements in the Spinal Cords and Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis

The results suggest that an immunological process involving the specific expansion of Vbeta2 TCR-positive T-cells may be important in the pathogenesis of ALS.

T cells in amyotrophic lateral sclerosis

  • T. Holmøy
  • Biology
    European journal of neurology
  • 2008
The evidence for T cells as pathogenic players and therapeutic targets in ALS is reviewed and it is possible that T cells can be induced to slow motor neuron destruction and facilitate repair in ALS.

Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease

It is shown for the first time that adoptive transfer of CD3‐activated Tregs to MPTP‐intoxicated mice provides greater than 90% protection of the nigrostriatal system through modulation of microglial oxidative stress and inflammation.